The antitumor effects induced by anti-CD4 depleting monoclonal antibodies (anti-CD4 mAb) were found to be mediated by CD8+ cytotoxic T lymphocytes (CTLs), which increased in the draining lymph node (dLN) and tumor after anti-CD4 mAb treatment (7). Here, CD8A is linked to neoplasm.